Sanofi: COVID shot has 72% Omicron efficacy

Freitag, 24. Juni 2022 09:44

Sanofi S.A. and GlaxoSmithKline plc (GSK) announced on Friday the results of their COVID-19 vaccine trial, which showed a 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19. Against the Omicron variant, the trial demonstrated a 72% efficacy in all adults with symptoms.

The companies added that the trial, which has so far included around 23,000 participants, also proved that the shot has "a favorable safety and tolerability profile." They stressed that these results are the first ever reported efficacy data modeled on the Beta variant antigen in an Omicron environment.

Relevante Links: Sanofi S.A.GlaxoSmithKline PLC
Baha Breaking News (BBN) / DJ